



CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel: 09152729959/9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

0065VF001784 AGE: 33 Years SEX: Female ACCESSION NO:

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

CLIENT PATIENT ID: **REFERRING DOCTOR:** SELF

Test Report Status	<u>Final</u>	Results Biological Reference Interval	Units
--------------------	--------------	---------------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **BLOOD COUNTS, EDTA WHOLE BLOOD** 12.0 - 15.0 HEMOGI OBIN 13.0 g/dL METHOD: PHOTOMETRIC MEASUREMENT 38-48 RED BLOOD CELL COUNT 4.52 mi**l**/μL METHOD: COULTER PRINCIPLE WHITE BLOOD CELL COUNT 4.0 - 10.0 7.40 thou/µL METHOD: COULTER PRINCIPLE PLATELET COUNT 202 150 - 410thou/µL METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY **RBC AND PLATELET INDICES HEMATOCRIT** 40.3 36.0 - 46.0 % METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR VOL 89.1 83.0 - 101.0 fL METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HGB. 27.0 - 32.0 28.8 pg METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN 32.3 31 5 - 34 5 g/dL CONCENTRATION METHOD: CALCULATED PARAMETER MENTZER INDEX 19.7 RED CELL DISTRIBUTION WIDTH High 11.6 - 14.0 % 14.6 METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM fL MEAN PLATELET VOLUME 11.8 High 6.8 - 10.9 METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM **WBC DIFFERENTIAL COUNT - NLR** SEGMENTED NEUTROPHILS 59 40 - 80% METHOD: VCSN TECHNOLOGY/ MICROSCOPY ABSOLUTE NEUTROPHIL COUNT 4.37 2.0 - 7.0thou/µL METHOD: CALCULATED PARAMETER LYMPHOCYTES 32 20 - 40% METHOD: VCSN TECHNOLOGY/ MICROSCOPY ABSOLUTE LYMPHOCYTE COUNT 2.37 1.0 - 3.0thou/µL METHOD: CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8 METHOD: CALCULATED **EOSINOPHILS** 3 1.0 - 6.0 %



Page 1 Of 16 Scan to View Report





CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
METHOD: VCSN TECHNOLOG	GY/ MICROSCOPY				
ABSOLUTE EOSINOPHI	L COUNT	0.22		0.02 - 0.50	thou/µL
METHOD : CALCULATED PAR	AMETER				
MONOCYTES		6		2.0 - 10.0	%
METHOD: VCSN TECHNOLOG	GY/ MICROSCOPY				
ABSOLUTE MONOCYTE	COUNT	0.44		0.2 - 1.0	thou/µL
METHOD : CALCULATED PAR	AMETER				
BASOPHILS		0		0 - 1	%
METHOD: VCSN TECHNOLO	GY/ MICROSCOPY				
ABSOLUTE BASOPHIL (COUNT	0.00	Low	0.02 - 0.10	thou/µL
METHOD : CALCULATED PAR	AMETER				
ERYTHRO SEDIMENT	ATION RATE, BLOOD				
SEDIMENTATION RATE	(ESR)	27	High	0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHO	DTOMETRICAL CAPILLARY STOPPED FLO	W KINETIC ANALYSIS)			
GLUCOSE, FASTING,	PLASMA				
GLUCOSE, FASTING, PL	_ASMA	85		74 - 99	mg/dL
METHOD : SPECTROPHOTOM	ETRY HEXOKINASE				
GLYCOSYLATED HEM	OGLOBIN, EDTA WHOLE BL	OOD			
GLYCOSYLATED HEMOO	GLOBIN (HBA1C)	5.0		Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
METHOD : ION- EXCHANGE I	HPLC				
MEAN PLASMA GLUCOS	SE	96.8		< 116.0	mg/dL
METHOD : CALCULATED PAR	AMETER				
GLUCOSE, POST-PRA	NDIAL, PLASMA				
GLUCOSE, POST-PRANI METHOD: SPECTROPHOTOM	,	80		70 - 139	mg/dL
CORONARY RISK PRO	OFILE (LIPID PROFILE), SE	RUM			
CHOLESTEROL		196		Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE









CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
TRIGLYCERIDES	AFTDY ENTRANTIC ENDOCANT WITH CLV	64		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
HDL CHOLESTEROL	METRY, ENZYMATIC ENDPOINT WITH GLY	55		Low HDL cholesterol	mg/dL
				< 40 High HDL cholesterol > / = 60	
METHOD : SPECTROPHOTON	METRY, HOMOGENEOUS DIRECT ENZYMAT	TIC COLORIMETRIC		, , ,	
DIRECT LDL CHOLESTE	EROL	133	High	Optimal: < 100 Near optimal/above optimal: 10129 Borderline high: 130 - 159 High: 160 - 189 Very high: > / = 190	mg/dL 00 -
METHOD : SPECTROPHOTON	METRY, HOMOGENEOUS ENZYMATIC COLO	DRIMETRIC			
NON HDL CHOLESTER	DL	141	High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
METHOD : CALCULATED PAR	RAMETER			-, 3 ,	
CHOL/HDL RATIO		3.6		Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
METHOD : CALCULATED PAR	RAMETER			ğ	
LDL/HDL RATIO		2.4		Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate Risk: 3.1 6.0 High Risk: > 6.0	-
METHOD : CALCULATED PAR		12.0			/ -
VERY LOW DENSITY LI		13.0		< or = 30.0	mg/dL
METHOD : CALCULATED PAR					
LIVER FUNCTION PR	OFILE, SERUM				
BILIRUBIN, TOTAL METHOD: SPECTROPHOTON	METRY, COLORIMETRIC -DIAZO METHOD	0.90		Upto 1.2	mg/dL
BILIRUBIN, DIRECT	,	0.33 I	Hiah	0.0 - 0.2	mg/dL
•	4ETRY, JENDRASSIK & GROFF - DIAZOTIZ		_	0.0	9, a.
BILIRUBIN, INDIRECT	,	0.57		0.1 - 1.0	mg/dL
METHOD : CALCULATED PAR	RAMETER				9, 42
TOTAL PROTEIN	 	7.6		6.0 - 8.0	g/dL
	METRY, COLORIMETRIC -BIURET, REAGEN				<i>31</i> ==











CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE

PATIENT ID: SREOF05038927

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference I	Interval Units
AL PUINTN	4.5	207 404	. 7.11
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(•	2.0 - 3.5	الم الم
GLOBULIN METHOD: CALCULATED PARAMETER	3.1	2.0 - 3.5	g/dL
	1,5	1,0 - 2,1	RATIO
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1,5	1.0 - 2.1	KATIU
	18	Unto 22	U/L
ASPARTATE AMINOTRANSFERASE (AST/SGOT METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL P	•	Upto 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	17	Upto 33	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL P		•	U/L
ALKALINE PHOSPHATASE	95	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFC		33 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	17	< 40	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMET			U/L
LACTATE DEHYDROGENASE	160	< 223	U/L
METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE		< 225	0/ L
SERUM BLOOD UREA NITROGEN	ov nec		
BLOOD UREA NITROGEN	16	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRI		0 - 20	mg/uL
CREATININE, SERUM	C		
•	0.69	0.60 1.10	ma/dl
CREATININE METHOD: SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICR	0.68	0.60 - 1.10	mg/dL
BUN/CREAT RATIO	ATE KINETIC - KATE BLANKED -	IFCC-IDMS STANDARIZED	
	22.40	Ui-b 0 15	
BUN/CREAT RATIO	23.40	High 8 - 15	
METHOD : CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	3.9	2.4 - 5.7	mg/dL
METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMET	FRIC- URICASE		
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.6	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURE	T, REAGENT BLANK, SERUM BLAN	IK	
ALBUMIN, SERUM			
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING		
GLOBULIN			
GLOBULIN	3.1	2.0 - 3.5	g/dL
METHOD: CALCULATED PARAMETER			









CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel: 09152729959/9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	Report Status <u>Final</u> Results Biological F		Biological Reference	Reference Interval Units	
ELECTROLYTES (NA/	K/CL), SERUM				
SODIUM		137	136 - 145	mmo l /L	
METHOD : ISE INDIRECT		2.00	25 54		
POTASSIUM METHOD: ISE INDIRECT		3.90	3.5 - 5.1	mmo l /L	
CHLORIDE		102	98 - 106	mmo l /L	
METHOD: ISE INDIRECT		102	30 100	mmol, E	
PHYSICAL EXAMINA	TION, URINE				
COLOR		PALE YELLOW			
APPEARANCE		SLIGHTLY HAZY			
SPECIFIC GRAVITY		1.015	1.010 - 1.030		
CHEMICAL EXAMINA	TION, URINE				
PH		6.5	5.00 - 7.50		
PROTEIN		NOT-DETECTED	NOT DETECTED		
GLUCOSE		NOT-DETECTED	NOT DETECTED		
KETONES		NOT-DETECTED	NOT DETECTED		
BLOOD		NOT-DETECTED	NOT DETECTED		
BILIRUBIN		NOT-DETECTED	NOT DETECTED		
UROBILINOGEN		NOT-DETECTED	NORMAL		
NITRITE		NOT-DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE		NOT-DETECTED	NOT DETECTED		
MICROSCOPIC EXAM	IINATION, URINE				
PUS CELL (WBC'S)		1-2	0-5	/HPF	
EPITHELIAL CELLS		10-15	0-5	/HPF	
ERYTHROCYTES (RBC'S	S)	NOT DETECTED	NOT DETECTED	/HPF	
CASTS		NOT DETECTED			
CRYSTALS		NOT DETECTED			
BACTERIA		NOT DETECTED	NOT DETECTED		
YEAST		NOT DTECTED	NOT DETECTED		
METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM					

NOTE: KINDLY EXERT CAUTION DURING INTERPRETATION OF FINDINGS REPORTED IN URINALYSIS WHERE IN THE SAMPLE IS MORE THAN TWO HOURS OLD.

THYROID PANEL, SERUM











CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA

8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
ТЗ	121.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester105.0 - 230.0 2nd Trimester129.0 - 262.0 3rd Trimester135.0 - 262.0	ng/dL
METHOD: COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY		
T4	7.41	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
METHOD: COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY		
TSH 3RD GENERATION	2,210	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	μIU/mL

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

PAPANICOLAOU SMEAR

CONVENTIONAL GYNEC CYTOLOGY **TEST METHOD**

SPECIMEN TYPE TWO UNSTAINED CERVICAL SMEARS RECEIVED.

2CV-13323

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SPECIMEN ADEQUACY SMEARS ARE SATISFACTORY FOR EVALUATION.

MICROSCOPY THE SMEARS SHOW MAINLY INTERMEDIATE SQUAMOUS CELLS, FEW

SUPERFICIAL SQUAMOUS CELLS, OCCASIONAL CLUSTERS OF

ENDOCERVICAL CELLS AND FEW POLYMORPHS.

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY, 2014, 3rd Edition) RE-TESTING AT 3 YEARS

- 1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.
- 2) No cytologic evidence of hpv infection in the smears studied.
- 3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.

STOOL: OVA & PARASITE

COLOUR BROWN









CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA

8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Results Biological Reference		
CONSISTENCY	SEMI FORMED			
ODOUR	FAECAL			
MUCUS	NOT DETECTED	NOT DETECTED		
VISIBLE BLOOD	ABSENT	ABSENT		
POLYMORPHONUCLEAR LEUKOCYTES	NOT DETECTED	0 - 5	/HPF	
METHOD: MICROSCOPIC EXAMINATION				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
METHOD: MICROSCOPIC EXAMINATION				
MACROPHAGES	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION				
CHARCOT-LEYDEN CRYSTALS	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION				
TROPHOZOITES	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION				
CYSTS	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED			
OVA	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION LARVAE	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED		
ADULT PARASITE	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED			
OCCULT BLOOD	NOT DETECTED	NOT DETECTED		
METHOD : MODIFIED GUAIAC METHOD		1101 52120125		
ABO GROUP & RH TYPE, EDTA WHOLE BLO	OOD			
ABO GROUP	0			
METHOD : HAEMAGGLUTINATION (AUTOMATED)	-			
RH TYPE	POSITIVE			
METHOD: HAEMAGGLUTINATION (AUTOMATED)				
XRAY-CHEST				
IMPRESSION	NO ABNORMALITY DETECTED			
TMT OR ECHO				
TMT OR ECHO	NORMAL			
ECG				
ECG	WITHIN NORMAL LIM	ITS		
MEDICAL HISTORY	WITHIN NONTAL LIM	113		
MEDICAL DISTORT				

CVS 2ND DOSE.



RELEVANT PRESENT HISTORY

Page 7 Of 16 Scan to View Report





CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030**

DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

> PATIENT ID: SREOF05038927

PATIENT NAME: SREOSHI CHATTERJEE

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units Fina

RELEVANT PAST HISTORY LSCS - 2021.

CARTILAGE TRANSFER SURGERY - 2021.

RELEVANT PERSONAL HISTORY NOT SIGNIFICANT

MENSTRUAL HISTORY (FOR FEMALES) **IRREGULAR**

LMP (FOR FEMALES) LMP DATE: 13.05.2022

RELEVANT FAMILY HISTORY HYPERTENSION. HEART DISEASE.

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HISTORY OF MEDICATIONS

HEIGHT IN METERS 1.56 mts

WEIGHT IN KGS. 57 Kgs BMI 23 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **HEALTHY BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE **NORMAL** SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION **NORMAL TEMPERATURE NORMAL**

PULSE 70/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **BRUIT**

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

105/72 MM HG mm/Hg

(SUPINE) **NORMAL**

PERICARDIUM APEX BEAT **NORMAL**









CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST)
MUMBAI, 400093

MAHARASHTRA, INDIA Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HEART SOUNDS S1, S2 HEARD NORMALLY

MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL

MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER NOT PALPABLE SPLEEN NOT PALPABLE

HERNIA NORMAL

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL
CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL EYELIDS NORMAL EYE MOVEMENTS NORMAL CORNEA NORMAL

DISTANT VISION RIGHT EYE WITH GLASSES WITH GLASSES NORMAL (6/6)
DISTANT VISION LEFT EYE WITH GLASSES WITH GLASSES NORMAL (6/6)
NEAR VISION RIGHT EYE WITH GLASSES WITHIN NORMAL LIMIT (N/6)
NEAR VISION LEFT EYE WITH GLASSES WITHIN NORMAL LIMIT (N/6)

COLOUR VISION NORMAL (17/17)



Page 9 Of 16





CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT **NEW DELHI 110030**

DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results **Biological Reference Interval** Units Test Report Status Fina

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL HEAVY WITHIN NORMAL LIMIT

TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES CLEAR

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

SUMMARY

RELEVANT HISTORY CVS 2ND DOSE. NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS RAISED ESR (27)

URINE:-EPITHELIAL CELLS (10-15) RAISED SERUM BILIRUBIN DIRECT (0.33) RAISED NON HDL CHOLESTEROL (141) RAISED DIRECT LDL CHOLESTEROL (133)

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS LOW CALORIC DIET.

REDUCE FATTY FOOD IN DIET.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATFLET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT - NLRThe optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to

show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHRO SEDIMENTATION RATE, BLOOD-

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0 -1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin

3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:

Pre-diabetics: 100 - 125 mg/dL Diabetic: > or = 126 mg/dL

GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-



Page 10 Of 16 Scan to View Report





CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT **NEW DELHI 110030**

DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE PATIENT ID: SREOF05038927

0065VF001784 AGE: 33 Years SEX: Female ACCESSION NO:

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Test Report Status **Biological Reference Interval** Units Fina

Glycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood,

the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCc, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.

"Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient

References

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006,
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5

CORONARY RISK PROFILE (LIPID PROFILE), SERUM-

Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely, HDL cholesterol is inversely related to the risk for cardiovascular disease, It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE, includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol, It does not include triglycerides and may be best used in patients for whom fasting is difficult. LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic









CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030 DELHI INDIA** 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE

PATIENT ID: SREOF05038927

0065VF001784 AGE: 33 Years SEX: Female ACCESSION NO:

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units Fina

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma It is produced in the liver Albumin constitutes about half of the blood serum protein low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

SERUM BLOOD UREA NITROGEN-

Causes of Increased levels

Pre renal

- High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal
- Renal Failure

Post Renal

Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- STADH

CREATININE, SERUM-

Higher than normal level may be due to:

• Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- · Mvasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM-

Causes of Increased levels

Dietary

- High Protein Intake.Prolonged Fasting,
- Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM.

Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake
- OCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Limit animal proteins High Fibre foods
- Vit C Intake
 Antioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C. Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver, Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution,



Page 12 Of 16 高級 Scan to View Report





CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030**

DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

> PATIENT ID: SREOF05038927

PATIENT NAME: SREOSHI CHATTERJEE

0065VF001784 AGE: 33 Years SEX: Female ACCESSION NO:

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Test Report Status **Biological Reference Interval** Units Fina

increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUM-Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, THYROID PANEL, SERUM-

Triiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

Levels in TOTAL T4 TSH3G TOTAL T3 (μg/dL) 6.6 - 12.4 6.6 - 15.5 Pregnancy (µIU/mL) (na/dL) 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 81 - 190 100 - 260 First Trimester 2nd Trimester 6.6 - 15.5 100 - 260 3rd Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3

T4

(ng/dL) (µg/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9 New Born: 75 - 260

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well

documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

Reference:

- 1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.
- 2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.
 3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition

STOOL: OVA & PARASITE-

Acute infective diarrhoea and gastroenteritis (diarrhoea with vomiting) are major causes of ill health and premature death in developing countries. Loss of water and electrolytes from the body can lead to severe dehydration which if untreated, can be rapidly fatal in young children, especially that are malnourished, hypoglycaemic, and generally in poor health.

Laboratory diagnosis of parasitic infection is mainly based on microscopic examination and the gross examination of the stool specimen. Depending on the nature of the parasite, the microscopic observations include the identification of cysts, ova, trophozoites, larvae or portions of adult structure. The two classes of parasites that cause human infection are the Protozoa and Helminths. The protozoan infections include amoebiasis mainly caused by Entamoeba histolytica and giardiasis caused by Giardia lamblia. The common helminthic parasites are Trichuris trichiura, Ascaris lumbricoides, Strongyloides stercoralis, Taenia sp. etc ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE, HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.



Page 13 Of 16 高級 Scan to View Report







SREOF05038927

CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

ACCESSION NO: 0065VF001784

NEW DELHI 110030 DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA

PATIENT ID:

13/06/2022 13:13

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE

AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Units Fina

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr. Kshama P. **Biochemist**

Dr. Ekta Patil Microbiologist Dr.Jeenal Parikh,MD Histopathologist

Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief Of Lab - Mumbai













CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE

PATIENT ID: SREOF05038927

ACCESSION NO: 0065VF001784 AGE: 33 Years SEX: Female

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All Tests are performed and reported as per the turnaround time stated in the SRL Directory of services (DOS).
- 3. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 4. A requested test might not be performed if:
- a. Specimen received is insufficient or inappropriate specimen quality is unsatisfactory
 - b. Incorrect specimen type
- c. Request for testing is withdrawn by the ordering doctor or patient
- d. There is a discrepancy between the label on the specimen container and the name on the test requisition form

- 5. The results of a laboratory test are dependent on the quality of the sample as well as the assay technology.
- 6. Result delays could be because of uncontrolled circumstances. e.g. assay run failure.
- 7. Tests parameters marked by asterisks are excluded from the "scope" of NABL accredited tests. (If laboratory is accredited).
- 8. Laboratory results should be correlated with clinical information to determine Final diagnosis.
- 9. Test results are not valid for Medico- legal purposes.
- 10. In case of queries or unexpected test results please call at SRL customer care (Toll free: 1800-222-000). Post proper investigation repeat analysis may be carried out.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Page 15 Of 16







SREOF05038927

CLIENT CODE: C000138379 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030**

ACCESSION NO: 0065VF001784

DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA

PATIENT ID:

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: SREOSHI CHATTERJEE

DRAWN: RECEIVED: 11/06/2022 08:31 REPORTED: 13/06/2022 13:13

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

AGE: 33 Years

Test Report Status Results Units Fina

SEX: Female

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. Patient identity and demographic details are crucial for a correct report. Kindly check your Name / Age / Mobile number & Email ID on the test requisition form and receipt.
- 2. In case of collected specimen(s) referred to SRL / collected by patient, it is presumed that the sample belongs to the patient named or identified in the test requisition form. The referring Lab /collection authority is responsible for appropriate sample collection as per pre-requisites, its labelling and transport.
- 3. A fresh sample may be requested if the Quality or Quantity of received sample is unsatisfactory
- 4. SRL is committed to deliver reports on time. However, in unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event report may be delayed. SRL aims to keep this to minimal.
- 5. Kindly share all clinical details along with the specimen for accurate diagnosis. SRL may request for additional information for clinical co-relation as & when required
- 6. Tests once registered cannot be CANCELLED!

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



